Skip to main content
Mark Kay, MD, Medical Genetics, Stanford, CA

MarkAllanKayMD

Medical Genetics • Stanford, CA

Clinical Biochemical Genetics

Professor, Pediatrics - Human Gene Therapy, Stanford University Medical Center

Join to view full profile

Dr. Kay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kay's full profile

Already have an account?

Education & Training

  • Baylor College of Medicine
    Baylor College of MedicineMedical Genetics and Biochemical Genetics, 1990 - 1993
  • Baylor College of Medicine (Houston)
    Baylor College of Medicine (Houston)Residency, Pediatrics, 1987 - 1990
  • Other
    OtherClass of 1987

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2000 - 2020

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1997
  • Whos Who in Medicine and Healthcare Marquis Whos Who

Publications & Presentations

PubMed

Lectures

  • Biologic Therapeutics Seminar Series - Systems Approaches to Antibody-based Immunotherapy of Cancer 
    Washington University School of Medicine, Saint Louis, Missouri - 5/16/2012
  • Biologic Therapeutics Seminar Series - Hairy Cell Leukemia, Standard & Biologic Approaches 
    Washington University School of Medicine, Saint Louis, Missouri - 2/22/2012
  • Biologic Therapeutics Seminar Series - In Vivo Gene Transfer for Genetic Disease: Progress & Challenges 
    Washington University School of Medicine, Saint Louis, Missouri - 1/25/2012

Press Mentions

  • LogicBio Acquired by Alexion, AstraZeneca Rare Disease
    LogicBio Acquired by Alexion, AstraZeneca Rare DiseaseOctober 3rd, 2022
  • Mystery Hepatitis Cases in Kids Linked to Unexpected Viral Suspect
    Mystery Hepatitis Cases in Kids Linked to Unexpected Viral SuspectJuly 25th, 2022
  • Nuevocor Closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
    Nuevocor Closes US$24M Series A Financing to Advance Novel Gene Therapies for CardiomyopathiesJune 18th, 2021
  • Join now to see all

Grant Support

  • Molecular Evolution Strategies To Derive New Recombinant AAV VectorsNational Heart, Lung, And Blood Institute2009–2012
  • Hepatic Gene Transfer For Treatment Of Hemophilias A &BNational Heart, Lung, And Blood Institute2000–2012
  • Novel Sources Of Transplantable Beta-Cell ReplacementsNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2011
  • Studies On RNAI Based Delivery In VivoNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2011
  • RNAI For The Treatment Of Viral HepatitisNational Institute Of Allergy And Infectious Diseases2006–2011
  • Hepatic Gene Transfer For Treatment Of Hemophilias A&BNational Heart, Lung, And Blood Institute2005–2008
  • Improved Adenoviral Vectors For Hepatic Gene TherapyNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2006
  • RNAI - Based Therapies For HCV InfectionNational Institute Of Allergy And Infectious Diseases2005
  • Novel Aavs For Gene TherapyNational Heart, Lung, And Blood Institute2005
  • Gene Therapy For HemophiliaNational Heart, Lung, And Blood Institute2005
  • Gene Therapy For Hemophilia And Coronary Artery DiseaseNational Heart, Lung, And Blood Institute2000–2004
  • Transposon Based Gene TherapeuticsNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2002
  • Core--Vector ProductionNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2002
  • Mouse Model For HCV InfectionNational Institute Of Allergy And Infectious Diseases2000–2002
  • Isolated Liver Perfusion Raav &Nonviral Vector DeliveryNational Heart, Lung, And Blood Institute2000–2002
  • Conference On Gene Therapy 2001: A Gene OdysseyNational Institute Of Diabetes And Digestive And Kidney Diseases2001
  • Adjunct Immunotherapy For Adenoviral Gene TherapyNational Institute Of Diabetes And Digestive And Kidney Diseases1998–1999
  • Hepatic Gene Transfer For The Treatment Of Hemophilia BNational Heart, Lung, And Blood Institute1998–1999
  • Preclinical Hepatic Gene TherapyNational Center For Research Resources1997–1999
  • Pilot Study--Hepatic Gene Therapy For Hemophilia ANational Institute Of Diabetes And Digestive And Kidney Diseases1996–1999
  • Core--Vector FacilityNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1999
  • Gene TherapyNational Institute Of Allergy And Infectious Diseases1996–1999
  • Animal ModelsNational Institute Of Allergy And Infectious Diseases1996–1999
  • Adjunct Immunotherapy For Adenoviral Gene TherapyNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1997
  • Hepatic Gene Transfer For The Treatment Of Hemophilia BNational Heart, Lung, And Blood Institute1995–1997
  • Improved Adenoviral Vectors For Hepatic Gene TherapyNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1997
  • Hepatic Gene TherapyNational Institute Of General Medical Sciences1990–1992

Dr. Mark Kay, Dr. Mark Kay, MD, Dr. M Kay, Dr. Mark Allan Kay